Selexis (15 Biological Program Assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Selexis (15 Biological Program Assets) General Information

Description

Provider of technology services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The company offers SURE cell line development services and technology, which includes patented genetic elements that enable the users to increase recombinant protein production.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 18 chemin des Aulx
  • 1228 Plan-les-Ouates
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Selexis (15 Biological Program Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Selexis (15 Biological Program Assets)‘s full profile, request access.

Request a free trial

Selexis (15 Biological Program Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Selexis (15 Biological Program Assets)‘s full profile, request access.

Request a free trial